Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

INmune Bio Inc

INMB
Current price
7.7 USD -0.53 USD (-6.44%)
Last closed 8.28 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 152 324 480 USD
Yield for 12 month -15.85 %
1Y
3Y
5Y
10Y
15Y
INMB
21.11.2021 - 28.11.2021

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Address: 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

19.67 USD

P/E ratio

Dividend Yield

Current Year

+155 000 USD

Last Year

+374 000 USD

Current Quarter

+14 000 USD

Last Quarter

+28 000 USD

Current Year

+155 000 USD

Last Year

+374 000 USD

Current Quarter

+14 000 USD

Last Quarter

+28 000 USD

Key Figures INMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA
Operating Margin TTM -78692.86 %
PE Ratio
Return On Assets TTM -35.53 %
PEG Ratio
Return On Equity TTM -81.82 %
Wall Street Target Price 19.67 USD
Revenue TTM 131 000 USD
Book Value 1.57 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -63.2 %
Dividend Yield
Gross Profit TTM 374 000 USD
Earnings per share -1.92 USD
Diluted Eps TTM -1.92 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics INMB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History INMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation INMB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1044.4133
Price Sales TTM 1208.357
Enterprise Value EBITDA -5.4431
Price Book MRQ 4.9109

Financials INMB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators INMB

For 52 weeks

6.5 USD 14.74 USD
50 Day MA 10.06 USD
Shares Short Prior Month 1 917 597
200 Day MA 9.91 USD
Short Ratio 11.31
Shares Short 1 897 112
Short Percent 14.21 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics